MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Study 102 - comparable decreases in A1C levels
Study 102 compared the efficacy of meal-time AFRESA in combination with a long-acting basal insulin versus twice daily injections of pre-mixed insulin (a mixture of rapid-acting insulin and intermediate-acting insulin) in patients with type 2 diabetes. A total of 323 patients were randomized to the AFRESA group and 331 patients were randomized to the pre-mix group.
Over the 52-week period of this study, A1C levels decreased comparably in the two treatment groups, 0.59 in the AFRESA group and 0.71 in the pre-mix group. The 95% confidence interval (0.29%) of the between-group difference did not exceed the predetermined threshold of 0.40%, thereby establishing non- inferiority between AFRESA and pre-mixed insulin.
Other study highlights:
-- A comparable percentage of patients reached A1C target levels in each treatment group.
-- There was a significantly greater decrease in fasting blood glucose levels in the AFRESA group compared to pre-mixed insulin.
-- Patients in the AFRESA group gained significantly less weight than did patients in the pre-mix group.
-- Severe hypoglycemic events were significantly less common in the AFRESA group than in the pre-mix group
-- There were no between-group differences in pulmonary function measures, including FEV1 (forced expiratory volume in one second), FVC (forced vital capacity), DLCo (carbon monoxide diffusing capacity) and TLC (total lung capacity).
-- These preliminary results are subject to further statistical analysis.
Study 030 - no adverse effect on lung function
Study 030 compared the pulmonary safety of meal-time inhalation of AFRESA versus usual care (the comparator group). A total of 938 patients with type 1 and type 2 diabetes were randomized to the AFRESA group; 951 patients were randomized to the comparator group. An additional 164 subjects without diabetes were enrolled into a third arm in order to assess the effect of diabetes on pulmonary function.
The primary endpoint of Study 030 was pre-specified with the FDA as a between-group difference (AFRESA-treated vs. comparator group) of less than 50 mL per year in the decline from baseline measures of FEV1 over the entire study period. After two years of treatment, the difference between mean FEV1 values for the two treatment groups was 37 mL (95% CI: 14-60 mL) -- well within the 100 mL pre-defined limit. Non-inferior results were also observed in secondary measures of lung function, including FVC, TLC and DLCo.
Other study highlights:
-- On average, patients in the AFRESA group gained less weight than did patients in the comparator group or subjects without diabetes.
-- Comparable decreases were observed in A1C levels between the AFRESA- treated group and the comparator group
-- Severe hypoglycemic events were significantly less common in the AFRESA group compared to the comparator group.
These preliminary results are subject to further statistical analysis.
Dr.
About AFRESA
AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.
About
Forward-Looking Statements
This press release contains forward-looking statements, including
statements related to the promise for AFRESA, next steps in the Company's
clinical trial program, plans and timing for the submission of a new drug
application and expectations regarding potential position and use of AFRESA in
the market. Words such as "believes", "anticipates", "plans", "expects",
"intend", "will", "goal", "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are
based upon
SOURCE
CONTACT:
Chief Scientific Officer
of
+1-201-983-5064,
prichardson@mannkindcorp.com
Web site: http://www.mannkindcorp.com